RecruitingPhase 2NCT07013201
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Studying Pustulosis palmaris et plantaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- LEO Pharma
- Principal Investigator
- Medical ExpertLEO Pharma
- Intervention
- Delgocitinib cream(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (30)
- LEO Pharma Investigational Site, Fountain Valley, California, United States
- LEO Pharma Investigational Site, Douglasville, Georgia, United States
- LEO Pharma Investigational Site, West Bloomfield, Michigan, United States
- LEO Pharma Investigational Site, Elmhurst, New York, United States
- LEO Pharma Investigation Site, Mayfield Heights, Ohio, United States
- LEO Pharma Investigational Site, Portland, Oregon, United States
- LEO Pharma Investigational Site, Philadelphia, Pennsylvania, United States
- LEO Pharma Investigational Site, Surrey, British Columbia, Canada
- LEO Pharma Investigational Site, Winnipeg, Manitoba, Canada
- LEO Pharma Investigational Site, Fredericton, New Brunswick, Canada
- LEO Pharma Investigational Site, Hamilton, Ontario, Canada
- LEO Pharma Investigational Site, Markham, Ontario, Canada
- LEO Pharma Investigational Site, Waterloo, Ontario, Canada
- LEO Pharma Investigational Site, Montreal, Quebec, Canada
- LEO Pharma Investigational Site, Bad Bentheim, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07013201 on ClinicalTrials.govOther trials for Pustulosis palmaris et plantaris
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07513142PPP Versus Corticosteroid for Thigh Muscle InjuriesAndrews Research & Education Foundation
- RECRUITINGPHASE4NCT07503652Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar PustulosisFirst Hospital of China Medical University
- RECRUITINGPHASE3NCT07219420A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisUCB Biopharma SRL
- RECRUITINGNANCT07270003A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar PustulosisXijing Hospital